TrialClinical cancer research : an official journal of the American Association for Cancer Research2010

K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate.

B Douglas Smith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.